Bluejay和Arbutus的新治疗显示,防治乙型和丁型肝炎的成功率很高。 New treatments from Bluejay and Arbutus show high success rates in fighting hepatitis B and D.

在治疗慢性乙型肝炎和D型肝炎的研究中,Bluejay Therapeutics和Arbutus Biopharma均报告了有前途的结果.Bluejay的BJT-778在乙型肝炎的第二阶段研究中显示出100%的病毒反应率.Arbutus的RNAi治疗药物imdusiran与基化干扰素结合,在乙型肝炎患者中实现了50%的功能治愈率. Bluejay Therapeutics and Arbutus Biopharma have each reported promising results in treating chronic hepatitis B and D. Bluejay's BJT-778 showed a 100% virologic response rate in a Phase 2 study for hepatitis D. Arbutus' RNAi therapeutic, imdusiran, combined with pegylated interferon, achieved a 50% functional cure rate in hepatitis B patients. 此外,Barinthus生物治疗法VTP-300与硝化硫结合导致23%的病人丧失HBSAg,并显示有可能停止抗病毒治疗而不复发。 Additionally, Barinthus Biotherapeutics' VTP-300 combined with nivolumab led to HBsAg loss in 23% of patients and showed potential for discontinuing antiviral treatment without relapse. 所有研究都显示一般安全情况良好。 All studies showed generally good safety profiles.